secwatch.observer — SEC 8-K summary
======================================

Issuer:     Curanex Pharmaceuticals Inc (CURX)
CIK:        0002025942
Form:       8-K
Filed at:   2026-10-19T21:15:25+00:00
Accession:  0001493152-26-047614
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Curanex faces two putative securities class actions over August 2025 IPO disclosures
--------------------------------------------------------------------------------

- Daymond Morales filed Action 1 on July 23, 2026 in New York Supreme Court (Index 159271/2026) against Curanex and underwriters Dominari, Pacific Century and Revere.
- Robert Lovett filed Action 2 on Sept. 14, 2026 (Index 655238/2026) against Curanex, its former CFO, directors, auditor and the same IPO underwriters.
- Both suits allege Sections 11 and 12(a)(2) violations over the August 2025 IPO offering documents, citing stock-price manipulation risks and underwriter due-diligence and AML deficiencies.
- Curanex says neither complaint asserts fraud against it, intends to defend vigorously; response deadlines are Nov. 15, 2026 for Morales and Dec. 11, 2026 for Lovett.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/0001493152-26-047614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-047614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer